Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice

• Published in: Frontiers in oncology Vol. 13; p. 1266369
• Main Authors: Rosinha, Alina, Rabaça, Carlos, Calais, Fernando, Pinto, João Moreira, Barreira, João Vasco, Fernandes, Ricardo, Ramos, Rodrigo, Fialho, Ana Cristina, Palma Dos Reis, José
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 2023
• Subjects: high-risk; identification; non-metastatic castration-resistant prostate cancer; Oncology; prostate-specific antigen; prostate-specific antigen doubling time; standardization; standardization; identification; high-risk; prostate-specific antigen doubling time; non-metastatic castration-resistant prostate cancer; prostate-specific antigen
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2023.1266369

Non-metastatic castration-resistant prostate cancer (nmCRPC) represents a challenging disease state in prostate cancer care. nmCRPC patients with a high risk of progression to metastatic disease who are identified by a prostate-specific antigen doubling time (PSADT) ≤10 months are eligible for treatment with the novel androgen receptor inhibitors (ARIs), shown to delay disease progression and extend survival. However, nmCRPC is often unexploited in clinical practice due to a lack of standardization in the methodology and in the tools used for its identification. In this article, a group of Urology and Oncology specialists with acknowledged expertise in prostate cancer reviews the state of the art in the management of high-risk nmCRPC patients, identifies gaps and unmet needs, and proposes strategies to optimize the identification of this patient subgroup in the clinical practice and improve their health outcomes.